In November last year, the Biden administration proposed a new rule that would allow drugs like Wegovy and Zepbound to be ...

States that do provide coverage have tried to manage costs by putting prescribing limits on the GLP-1s. There’s also some ...

Dr. Daniel Drucker, an endocrinologist and a clinician-scientist at the University of Toronto and the Lunenfeld-Tanenbaum ...

The Trump administration has decided not to go forward with a proposal for Medicare and Medicaid to cover high-demand obesity ...

The decision counters a proposal by the Biden Administration to reimburse beneficiaries for the weight-loss medications.

Advances recognized by science’s most lucrative awards include high-energy physics experiments and groundbreaking weight-loss ...

Ozempic and similar semaglutide-based medications have been hailed as miracle drugs. Known as GLP-1 (glucagon-like peptide-1) ...

The Trump administration has decided not to expand Medicare and Medicaid coverage for popular obesity drugs, blocking a Biden ...

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on ...

Studies show that GLP-1 agonists can help patients lose 5-15% of their body weight when combined with diet and exercise.

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of ...